A Study ATG-101 in Patients With Metastatic/Advanced Solid Tumors and Mature B-cell Non-Hodgkin Lymphomas

Exclusion Criteria

• •1. Subjects with CNS tumors or known CNS metastases will be excluded.
• •2. Prior ATG-101 administration or a 4-1BB agonist.
• •3. Prior anti-tumor systemic therapy within 21 days(a period of 5 'half- lives') of the first dose of study treatment.
• •4. Radiotherapy with a wide field of radiation within 28 days.
• •5. With the exception of alopecia, any unresolved toxicities from prior therapy greater than Grade 1 (CTCAE v5.0) at the time of ICF signature.
• •6. Active infection, including hepatitis B and/or hepatitis C.
• •7. Have uncontrolled intercurrent illness, including but not limited to:
• •8. Inadequate bone marrow reserve or organ function.
• •9. History of hypersensitivity or history of allergic reactions attributed to drugs with a similar chemical or biologic structure or class to ATG-101.
• •10. Prior organ allograft transplantations.
• •11. Pregnant or nursing females.
• •12. Have a history of another primary malignancy within 3 years prior to starting study treatment. Exceptions are as follows: the disease under study; adequately treated basal or squamous cell carcinoma of the skin; cancer of the cervix in situ, etc.
• •13. In the opinion of the investigator, subject's complications or other conditions may affect protocol compliance or may be unsuitable for participation in the study.